PT - JOURNAL ARTICLE AU - Shinya Tsuzuki AU - Norio Ohmagari AU - Philippe Beutels TI - The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan AID - 10.1101/2021.08.19.21262267 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.19.21262267 4099 - http://medrxiv.org/content/early/2021/08/21/2021.08.19.21262267.short 4100 - http://medrxiv.org/content/early/2021/08/21/2021.08.19.21262267.full AB - At present, there is scarce evidence about how much burden the isolation of COVID-19 patients is. We aimed to assess the differences between COVID-19 and other influenza like illnesses in disease burden brought by isolation. We conducted an online questionnaire survey of 302 people who had COVID-19 or other influenza-like illnesses (ILIs) and compared the burden of isolation due to sickness with one-to-one propensity score matching. The primary outcomes are the duration and productivity losses of isolation, the secondary outcome is quality of life (QOL) valuation on the day of the survey. Acute symptoms of outpatient COVID-19 and other ILIs lasted 17 (interquartile range [IQR] 9-32) and 7 (IQR 4-10) days, respectively. The length of isolation due to COVID-19 was 18 (IQR 10-33) days and that due to other ILIs was 7 (IQR 4-11) days, respectively. The monetary productivity loss of isolation due to COVID-19 was 1424.3 (IQR 825.6-2545.5) USD and that due to other ILIs was 606.1 (IQR 297.0-1090.9) USD, respectively. QOL at the time of the survey was lower in the COVID-19 group than in the “other ILIs” group (0.89 and 0.96, p = 0.001). COVID-19 infection imposes a substantial disease burden, even in patients with non-severe disease. This burden is larger for COVID-19 than other ILIs, mainly because the required isolation period is longer.Competing Interest StatementPB reports previous unrelated grants from Pfizer, GSK, and the European Commission IMI. The other authors declare no conflicts.Funding StatementThis research was funded by JSPS KAKENHI [Grant number 18K17369], a grant for the National Center for Global Health and Medicine [20A05] and the Health and Labor Sciences Research Grant, Research for risk assessment and implementation of crisis management functions for emerging and re-emerging infectious diseases. PB acknowledges support from the Epipose project from the European Union's SC1- PHE-CORONAVIRUS-2020 programme, project number 101003688, during the conduct of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Ethics Committee of the Center Hospital of the NCGM (NCGM-G-004001-01).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon request to the corresponding author. The data are not publicly available due to privacy or ethical restrictions.